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Abstract 
 
Background: COVID-19 is an infectious disease that started in Wuhan, China in late 2019 
and later spread around the world. Diabetes has been recognized as a possible risk factor for 
COVID-19 complications. 
Objective: ISPAD investigated perceptions, challenges and experience of healthcare 
professionals (HCP) taking care of children and young people with diabetes world-wide 
during COVID-19 pandemic.  
Methods: From 21st April to 17th May 2020, during COVID-19 pandemic, a web-based 
survey was sent to ISPAD members and former participants of ISPAD conferences by email.  
Results: Responders from 215 diabetes centres from 75 countries completed the survey. 
Majority were from UK (35; 16.3%), USA (20; 9.3%) and India (15; 7%). HCP were mostly 
pediatric endocrinologists (64%). During COVID-19 pandemic, 16.5% of responders 
continued face-to-face consultation while most changed to telephone (32%) or video (18%) 
consultations. 19% reported a shortage of medical supplies. 22% reported a delay in 
diagnosis of patients with new-onset diabetes, while 15% reported a higher incidence of 
DKA. 12% reported having one or more patients with COVID-19. Most of the 86 children 
and adolescents with diabetes and COVID-19 had only mild/moderate symptoms, while 5 
required admission to an intensive care unit. No deaths were reported.  
Conclusions:  This large global survey during COVID-19 pandemic showed that many HCP 
adapted to the pandemic by resorting to telemedicine. One fourth of HCP reported delays in 
diagnosis and an increased rate of DKA. The emergence of COVID-19 pandemic had an 
important impact on family’s behaviour that might have led to increase in DKA presentation. 
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Introduction 
 
Coronaviruses are a large family of viruses that can cause disorders ranging from a mild cold 
to severe diseases. In December 2019, a novel coronavirus called severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of COronaVIrus Diasease 
(COVID-19). Typical symptoms of COVID-19 include fever, cough, shortness of breath, and 
muscle pain [1]. In the time frame studied, a large cohort with COVID-19 from China 
showed that illness severity can range from mild (81%), severe (14%) to critical (5%). All 
deaths occurred among patients with critical illness and the overall case fatality rate was 
2.3% [2].Moreover, pooled rates of ICU admission, acute respiratory distress syndrome and 
mortality reported in another systematic review and meta-analysis were 10.9%, 18.4% and 
4.3%, respectively [3].  
Several data suggest that most people with COVID-19 may have comorbidities, the most 
prevalent of which are diabetes, cardiovascular disease, and hypertension [4]. In England, a 
nationwide analysis demonstrates that all types of diabetes are independently associated with 
a significant increased risk of in-hospital death with COVID-19[ 5].  
However, it is reassuring to hear that, at least according to some reports, young people, with 
or without diabetes, are coping better with COVID-19 infection [6]. Of 2,572 laboratory-
confirmed cases aged 18 years or younger in the US, none had type 1 nor type 2 diabetes but 
had other condition such as chronic lung disease and cardiovascular disease [7] or no chronic 
conditions at all [8]. 
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COVID-19 pandemic has forced dramatic changes in the delivery of healthcare landscape, 
and healthcare professionals (HCP) are making unprecedented modifications to healthcare 
systems, social services as well as attitude and management of children living with 
diabetes.To the best of our knowledge, we do not have established guidelines for managing 
COVID-19 in children, adolescents and young adults with diabetes. Therefore, we conducted 
this survey to gain an understanding of the patterns of practice of HCP registered in the 
database of the International Society for Pediatric and Adolescent Diabetes (ISPAD), who are 
likely to be taking care of children and adolescents with diabetes. This survey should help to 
identify different management strategies, challenges, knowledge and practice of HCP caring 
for pediatric patients with diabetes during COVID-19 pandemic so we can guide our future 
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Methods 
 
Study setting and design 
This is a cross-sectional electronic survey conducted over a four-week period from 21st April 
to 17th May 2020 under the auspices of ISPAD. The answers were entered into a web-based 
commercial software (Google Forms, Google LLC, California, United States) which is a 
collaborative web survey software created by Google. A Google Form is automatically 
connected to a spreadsheet, responses can be saved there and subsequently analysed.  
The target population was identified from the ISPAD HCP database (ISPAD members and 
former participants of ISPAD conferences and post-graduate courses). Respondents were 
asked to describe themselves concerning specialties, and volume of practice. They all 
received an initial invitation by e-mail that explained the rationale and what was required 
from the responders, followed by two reminder e-mails over 3 weeks for non-responders. If 
responders belong to the same centre, this was considered as a single response. All subjects 
provided explicit informed consent electronically to voluntary participate before they could 
proceed to the survey questions. The voluntary nature and the strict confidentiality in which 
data were analysed and reiterated.  Responses were collected automatically, stored 
electronically, and interpreted via linkage to spreadsheet. Summary statistics were prepared 
for responses to each question.  
The survey  
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The survey questions were developed by six pediatric endocrinologists. The survey was sent 
to about 2,300 HCP. A direct electronic link of the survey and consent was sent to the HCP 
by email and also via social media platforms (Facebook, Twitter, and LinkedIn). The 
completion of the survey took no more than twenty minutes. It was created in an online 
format with 47 questions divided into five sections. The first section concerns targeted HCP 
consent to participate in the survey and confirm their voluntary participation, and the 
following section included responders’ professional and practice profiles.  Three questions 
were aimed to define the professional profile of the responders, size of their clinic and their 
country of practice. To further understand challenges and changes that HCP have had to 
make in caring for children and adolescents with diabetes during the pandemic, the next 
section included a set of questions focused on diabetes management. The questions covered 
the HCP’s perceptions and practices including medication prescriptions, their availability, 
how they managed education sessions, acute complications seen, special considerations on 
use of concomitant drugs, blood glucose measurement, parents’ beliefs and psychological 
aspects faced. The last two sections included questions sought to characterise the profile of 
patients who tested positive for SARS-CoV-2 virus, including their characteristics, clinical 
presentation, diagnosis and treatment (the full version of the survey is available as a 
supplemental material). 
Statistical analysis 
Analysis of data was performed using Google Sheets. Descriptive statistics were used to 
present demographic data and to evaluate knowledge, attitudes and perceptions of HCP 
during COVID-19 pandemic. Quantitative variables were described in the form of mean and 
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standard deviation, and qualitative variables were described as number and percentage. Some 
questions were open-ended questions.  
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Results 
Responders’ professional and practice profiles 
In total we received 303 responses to the survey. Since for some center more than one 
response was received, we merged all the responders from the same center and considered it 
as one response. A convenient sample of 215 diabetes centers from 75 countries participated 
in the study. The majority of participants were form UK (35; 16.3%), followed by US (20; 
9.3%) and India (15; 7%). Among the responders 193 (64%) were pediatric endocrinologists, 
46 (15%) pediatricians with interest in diabetes, 26 (9%) nurse practitioners. The remaining 
were dietitians, trainee, diabetes educator and adult physicians. Majority of the participants 
(72.5%) had clinic size of more than 100 children with diabetes [Table 1]. 
Perceptions and practices of HCP towards diabetes during COVID-19  
During COVID-19 pandemic, face-to-face consultation has been maintained by 16.7% of 
responders, and only once adequate personal protective equipment has been provided. Most 
of the HCP offered only phone call (32%) and video consultations (18%) for existing 
patients. However, for patients with new onset diabetes, a majority of HCP (38%) offered 
face-to-face education wearing appropriate personal protective equipment followed by phone 
calls (25.5%) and video consultations (22%) [Table 1]. 
We asked if any shortage of supply has been perceived as a result of COVID-19 where there 
previously had not been shortages. There is very wide variation in insulin and supply refill 
prescription duration, varying from 1 month to always [Table 1]. Scarcity of any diabetes 
supply has been observed only by 19%, while 65% had not had any shortage of supplies, and 
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16% of them were not aware of any challenging situation. Main shortage of diabetes care 
supplies have been glucose test strips (26%), basal and bolus insulins (22% each), glucose 
sensors (10.5%). 
Immune stimulants have been prescribed only by one fourth of the responders, most of them, 
however, at less than 50% of their pediatric diabetes population [Table 1]. 
 
General management practices of diabetes care during COVID-19  
Twenty-two percent of responders reported a potentially delayed diagnosis of children with 
new onset diabetes mellitus during the pandemic and 15% reported a higher incidence of 
DKA in their practice. [Table 2]. 
Coming to the potential fear of COVID-19, most participants (68%) had the feeling that 
caregivers/families avoided contact with the diabetes team during pandemic because of this 
fear. 
Management of children and young people with diabetes mellitus that were COVID-19 
positive 
Twelve percent of HCP reported caring for one or more patients with COVID-19 [Table 2]. 
Most of responders reported using RT-PCR SARS-CoV-2 as method to confirm the diagnosis 
(78%), using both nasal (56%) and oropharyngeal (37%) swab, while serologic tests and 
bronchi alveolar lavage were used in very few patients [Table 2]. 
Only a small number of pediatric patients with positive testing for COVID-19 were reported 
in this global survey: 61 with type 1 diabetes mellitus and 25 with type 2. 
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Their clinical characteristics and symptoms (generally mild or moderate, with just 5 patients 
admitted to ICU) have been summarized in [Table 2]. No deaths were reported. 
Most of them reported a contact with family member with a confirmed positive test, or 
clinical suspicion (50%), while in 12.5% of cases the caregiver was a healthcare worker 
confronted with a positive case. In 7.5% travel or residence in a location reporting cases 
during the last 2 weeks was described. In 30% of COVID-19 positive patients the source of 
contagion remains unknown [Table 2]. 
During the COVID-19 outbreak paracetamol was the most antipyretic drug used (81%), while 
very few used ibuprofen (4%) or a combination of both (12%). 
The responders reported that majority of patients did not observe false readings with 
continuous glucose monitoring (CGM) (93%). Among the ones who reported false readings, 
the most used intermittent scanned or real time CGM was FreeStyle Libre™ (43%), followed 
by Dexcom G6™ (27%) and Dexcom G5™ (24%) respectively. 
Regarding continuing to use of angiotensin-converting enzyme inhibitors (ACEi) drugs in 
patients with nephropathy and/or hypertension, only 25% of people using the drug (about 
50% of the sample), have been advised to interrupt the ACEi. Patients (12%) who continued 
ACEi did not report any complications. 
Anxiety and parental stress were the most reported psychological problems faced so far (31% 
and 24%, respectively) while few patients (15%) did not face any. 
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Discussion 
 
This is the first study to quantitatively investigate the perceptions, challenges and experience 
of HCP for children and adolescents with diabetes mellitus during COVID-19 pandemic. 
Since its outbreak in Wuhan, China, in December 2019 COVID-19 has spread to more than 
200 countries and has been labeled as pandemic [9]. Epidemiologic studies have consistently 
demonstrated that children are at lower risk of developing severe symptoms or critical illness 
compared with adults [10,11]. Despite many uncertainties, the COVID-19 pandemic 
recommendations in most countries include people with diabetes within the ‘at risk’ 
population.  ISPAD guidance for HCP reassured people from anecdotal reports coming from 
Wuhan, China, and Italy, stating that children with diabetes have not shown a different 
disease pattern compared to their peers and that children in general had less severe clinical 
manifestations than adults [12]. 
Diabetic ketoacidosis is an acute, major, life-threatening complication of diabetes. Early 
diagnosis of type 1 diabetes is essential to allow treatment to start as soon as possible. 
Although, 15% of responders reported increased incidence of DKA in children in their 
centers, delayed diagnosis and admission to hospital were seen in 22% of the centers. This 
would suggest that for a significant number of centers, newly diagnosis of type 1 diabetes 
would be postponed, and possibly they would be facing a similar rate of DKA during the 
pandemic, but with more severe DKA due to the delay of the diagnosis. In the midst of the 
COVID-19 pandemic, people are sheltering in place and practicing social distancing. Parents 
and caregivers are delaying seeking emergency help out of fear of being infected in the 
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hospital or due to the reduced service for non-COVID-19 care. Moreover, delayed diagnosis 
of new cases of type 1 diabetes could be due to the front-line health workers focusing on 
respiratory symptoms of the unwell child (with DKA), without considering type 1 diabetes as 
a potential diagnosis. Thus, anecdotal reports have suggested that as a result of delay in 
seeking medical attention, affected individuals have presented with more severe DKA [13].  
The importance of following public health measures of containment in addition to standard 
diabetes mellitus care and, whenever needed, the sick day management guidelines of ISPAD 
should be emphasized [14]. Emergency department doctors should remember general 
pediatric evaluation in the time of a pandemic, such as recently observed, to avoid the need 
for hospitalization and emergency. Pediatric diabetes teams should be informed immediately 
to avoid complications; recommendations should be produced as soon as possible to allow 
appropriate treatment to start [12]. We recommend that every opportunity should be taken to 
raise awareness of the symptoms of diabetes amongst parents, caregivers, school staff, and 
the general population. It is the role of HCP to urge experiencing symptoms to seek care for 
these life-threatening events. 
COVID-19 pandemic has forced a majority of the diabetologists to adapt to providing 
diabetes mellitus care remotely through telehealth. However, healthcare disparities continue 
to challenge availability of diabetes technologies for underprivileged communities. In a 
recent two case series, DKA was prevented via telemedicine by shared glucose data through 
Clarity™ or the share feature of CGM, and frequent insulin dose adjustments. Clinical 
outcomes were similar without any hospital admissions, thus saving significant cost [15]. 
Telemedicine and digital medicine also offer critically important approaches to improve 
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access, efficacy, efficiency, and cost-effectiveness of medical care for people with diabetes. It 
will be important to include these measures as well after the pandemic. Telemedicine, 
technology and digital healthcare have demonstrated their role in diabetes mellitus care 
during a period of crisis, and this experience may be used to convince payers and policy 
makers of the lasting benefits for this high-risk population, and to systemize them [16]. It is 
strongly encouraged to upgrade telehealth services by institutions to continue caring for 
patients, as well as protect the healthcare workers and community. 
Face-to-face consultation, with appropriate personal protective equipment, was used at 16.5% 
of the centers. This pandemic is bringing healthcare systems worldwide to the brink of 
collapse based on the rapidly increasing number of new severe infections, including the high 
rate of infections among frequently exposed healthcare professionals. Telemedicine or 
another virtual diabetes clinic can be a useful tool to ease data exchange between patients and 
HCP, as well as to reduce the number of physician-patient contacts. However, it is of note 
that even for newly diagnosed patients (for whom usually the face-to face education is the 
gold standard) more than 50% of patients received education via telehealth systems. 
Consequences of the lockdown for persons with diabetes could be absent or major, based on 
less exercise, changes in dietary habits (e.g., increased snacking, consumption of ‘comfort’ 
dense-calorie foods), restrictions in routine visits to the physician, and decreased availability 
of insulin and/or oral hypoglycemic agents. Although HCP kept insulin available for almost 
three months ahead and all insulin and technology companies announced that they did not 
anticipate disruptions of the medical supply line, 19% of responders had shortage in basic 
diabetes supplies: blood glucose test strips, basal and bolus insulins, as well as sensors for 
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CGM. This is an alarming fact that might lead to uncontrolled glycemia or worsening status 
of comorbid diseases in some region of the world. It should be emphasized to urge companies 
on providing all diabetes medical supplies around the globe. A link to their on-line shop for 
supplies should also be provided. Telehealth consultations should be supported, and virtual 
training sessions should be readily available. 
In our survey, 12% reported on COVID -19 positive patients. These were mainly type 1 and 
type 2 diabetes patients. In type 1 diabetes patients mean HbA1c was 7.6%, diabetes duration 
range 1-5 years, while for type 2 was 7.8% and diabetes duration range 3-10 years. It seems 
that most of cases were well controlled with standard therapy, and just few needed ICU 
admission; two adolescents with type 2 diabetes admitted to ICU required intubation and 
ventilation. Fortunately, no death was reported. A study from China reported that adults with 
diabetes had a significantly higher risk than people without, of severe pneumonia, release of 
tissue injury-related enzymes, excessive uncontrolled inflammatory responses, and 
hypercoagulable state associated with dysregulated glucose metabolism [17]. A recent study 
reported that a higher HbA1c level is associated with inflammation, hypercoagulability, and 
low oxygen saturation in COVID-19 patients, leading to a higher mortality rate [18]. 
As cardiovascular diseases and diabetes are strongly associated with elevated adipose tissue 
mass and low grade inflammation, a higher body mass index might be an important risk 
factor for a more severe course of the disease, particularly of pneumonia, in these people 
[19]. It is notable that the only ones who underwent intubation and ventilation were 2 
adolescents with type 2 diabetes. Knowledge about insulin resistance is also important, 
because it is among the strongest determinants of impaired metabolic health and cardiac 
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dysfunction. Measurement of anthropometrics and metabolic parameters is crucial as both 
might be useful in a hospital setting to assess the risk of a complicated course of disease in 
patients with positive COVID-19 tests [20]. 
Current knowledge suggests the virus can be transmitted through droplets, direct contact and 
aerosols. Droplets transmission may occur when respiratory droplets of an infected person, 
are ingested or inhaled by individuals nearby [21]. This is also been reported in our survey, as 
50% of respondents reveal direct contact with confirmed case among family members in 
previous two weeks. Though, 30% responded that the source of infection was unknown. 
Fecal shedding may be another source of transmission [ 22]. 
The clinical spectrum of COVID-19 is very heterogeneous. The most commonly reported 
symptoms were fever, cough, and hypo/hyperglycemia. However, shortness of breath. 
headache, myalgia, upper respiratory symptoms (e.g., sore throat and rhinorrhea) and 
gastrointestinal symptoms (e.g., nausea and diarrhea) can also occur, as recently reported 
[4,23]. Caution should be taken to potential hypoglycemic events either from severe illness 
and lack of food intake, ibuprofen should be handled with care as it could increase the 
hypoglycemic effect of insulin [24] and with the use of chloroquine in these subjects. Patient 
tailored therapeutic strategies, rigorous glucose monitoring and careful consideration of drug 
interactions seem to reduce adverse outcomes [25]. 
Another issue during this COVID-19 pandemic has been the use of immunostimulants to help 
preventing the disease. To date there is insufficient evidence to conclude that children with 
type 1 diabetes are immunocompromised. The evidence indicates that an 
immunocompromised state occurs only in the context of poor glycemic control and/or with 
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severe complications, such as DKA or in adults with vasculopathy and chronic kidney disease 
[26]. The link between catching COVID-19 infection and diabetes was explored in this 
survey and 75% of HCP responded that parents did not ask for immunostimulant treatments. 
Interestingly, about the 25% who were asked for immunostimulant supplement, there is not a 
specific region of the world where this habit is consistent, but it was spread in several 
countries. It is important to note that immune supporting effects of supplements and vitamins, 
in the context of the COVID-19, are not proven. Furthermore, attention to nutrition, protein 
intake and vitamin status is important for individuals with diabetes at any time and thus as 
well during this pandemic [1]. Although a few studies recommend vitamin C 
supplementation as an antioxidant [27] and higher doses of vitamin D in elderly in the first 
few weeks of COVID-19  infection [28] or those with vitamin deficiency[29], neither vitamin 
D nor vitamin C supplementation appears to have  any effect in protecting from COVID-19. 
Of all respondents 81% used paracetamol as antipyretic, in line with some non-confirmed 
recommendations which hypothesized that ibuprofen or other non-steroidal anti-
inflammatory drugs could be harmful for patients with COVID-19 [30]. 
A low percentage of responders reported false positive elevated CGM reading (7%), 
especially among FreeStyle Libre™ users, perhaps due to acetaminophen interference [31]; 
this kind of interference has been previously reported for several CGM systems, including 
FreeStyle Libre™ [32].  
In the lower respiratory tract, it appears that decreased angiotensin-converting enzyme 2 
(ACE2), which binds to the receptor binding domain of SARS-CoV-2 virus, could portend a 
higher risk of developing severe acute respiratory distress and lung injury [5,33]. For this 
This article is protected by copyright. All rights reserved.
reason, 25% of responders advised their patients to interrupt ACEi in advance. No substantial 
increase in the likelihood of a positive test for COVID-19 or in the risk of severe COVID-19 
was reported in association with five common classes of antihypertensive medications [34]. 
In fact, the American Heart Association and other major associations recommend their 
continued use [35]. Achieving glycemic targets should be the goal, no matter which drugs are 
being used. 
Anxiety and parenting stress were the most commonly seen psychological problems among 
our responders. Living with diabetes and managing the condition on a day-to-day basis are 
associated with heightened levels of anxiety and distress [36, 37]. In a recent study, 25% 
experienced diabetes distress at the beginning of the COVID-19 pandemic, which 
corresponds to what is found under normal circumstances [38-40]. A Danish study showed 
that people with diabetes have COVID-19-specific worries related to their disease which is 
associated with poorer psychosocial health. These worries should be addressed through 
support targeting specific questions and needs of individuals with diabetes as well as frequent 
updates on new knowledge regarding COVID-19 and diabetes mellitus [38].  
It is important to prioritize mental health in these stressful days for both patients and their 
families, which can have a big impact on diabetes control and blood glucose levels. People 
with diabetes are two to three times more likely to have depression. Use of technology to stay 
connected to friends and family; trying an online meeting or calling a friend may lessen the 
stress patients might experience. 
Strengths of our study are the global sourcing (215 centers in 75 countries) among HCP with 
a focus on pediatric diabetes and the timeliness of the survey, which was initiated very 
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shortly after substantial lockdown in most countries due to the COVID-19 pandemic. 
Although SARS-CoV-2 infection in adults includes persons with diabetes in the vulnerable, 
high risk population, our report suggests that children with diabetes do not belong to the high 
risk group. This might have some important implications for children with diabetes and the 
restart of school, since does not seem they have to be more cautious than their healthy peers. 
Limitations of the survey may be that we present observational data from some countries but 
not all where COVID-19 spread out, even if the most interested ones (by numbers of infected 
people and deaths) are all represented. While 15% reported a higher incidence of DKA, only 
registry data prospectively will show accurately any impact on the rates of DKA presentation. 
However, we acknowledge that the missed countries could have had different experience or 
knowledge in handling these patients. Relating to this issue we would like also to highlight 
that out of approximately 2300 emails sent, we received only 303 responses (13%). Even if in 
line with the answer rate to similar surveys, these low numbers could be due either to the 
pandemic itself and much less time to manage usual daily workload, and the fact that some of 
the email addresses could have been changed or not active anymore.   
Follow up survey could be of utmost importance to improve our knowledge and to evaluate 
the effects of COVID-19 over time. 
 
In conclusion, this large global survey, done with HCP coming from centers treating children 
and adolescents with diabetes, showed how HCP adapted their current practices during 
COVID-19 pandemics. Social isolation highly influenced patients care around the world, 
favoring remote consultation through telehealth/telemedicine as an option to maintain 
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assistance to patients with diabetes, in comparison to traditional face-to-face consultation. 
The great majority of centers did not have diabetes children COVID-19 positive, and from 
those who had, the majority had just mild/moderate disease course. The emergence of 
COVID-19 pandemic had an important impact on family’s behavior that might be associated 
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Table 1: Clinical profile, centre characteristics and patients feature during COVID19 
pandemic 
Characteristics (number of responses) Responses (%) 







Brazil, Germany, Netherlands, Portugal, Sweden 




9 (4.2) each 
7 (3.3) each 
5 (2.3) each 
4 (1.9) each 
3 (1.4) each 
Participants’ clinical role (303) 
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Pediatric Endocrinologist/diabetologist 
Pediatrician with interest in diabetes 
Nurse practitioner/registered nurse 




Primary care practitioner/family doctor with interest in diabetes 
Adult physician looking after pediatric or adolescent patients 











Children and young people aged 0-18 years with diabetes being looked after (301) 
Less than 100 
100-200 
201-500 





Current routine check-up (832) b 
Telephone consultation 
Video consultation 
Face to face consultation with appropriate PPE 
Sent SMS, use of cross-platform messaging (e.g. WhatsApp©) and emails for 
consultations 
Apps or Patient Portal 
Only newly diagnosed patients or patients in a complex social system visit our center 
As usual, no changes 
HbA1c drive through staff in PPE but not at hospital site 











Multidisciplinary team deliver education to patients with new onset type 1 diabetes (565) b 
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Face to face education wearing appropriate personal protective equipment (PPE)  
By Telephone  
Video consultation  
Via application  






Refill prescription period (303) 
Every month 
Every 3 months or less 
Every 6 months or less 
Every year 
Automatically from pharmacy 
As required 
Refill prescription is not allowed 









Shortage of any diabetes medical supplies (303) 
Yes 
No, everything was secured 




Main shortage of diabetes supplies (134) 
Glucose test strips 
Basal Insulin 
Bolus Insulin 
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Adaptations on blood or sensor glucose monitoring (237)  
No changes from usual practice  
Monitor blood glucose and review CGM data more frequently 
Check sick day management with diabetes team 
Review CGM data more frequently  
Change to CGM, when available  
Monitor blood glucose more frequently  
Strict hand hygiene 









Most used antipyretics (118) 
Paracetamol (acetaminophen)  
















CGM sensor affected during pandemic (37) 
Freestyle Libre 









Prescription of immunostimulants (301) 
None 225 (75) 
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Less than 10% 
Around 25% 
Around 50% 











Complications of using ACEi during pandemic (61) 
No patient with nephropathy or on ACEi 
No complications 




Most reported psychological effects (491) b 
Anxiety 
Parental stress 
None have had psychological problems so far 
Depression 
Insomnia/hypersomnia 
Eating disorder    
Panic attacks 















PPE: personal protective equipment; CGM: continuous glucose monitor: ACEi: Angiotensin-
converting-enzyme inhibitors 
a Remaining countries that contributed with two or less centers: Bulgaria, C1716hile, Indonesia, 
Japan, Liberia, Mexico, New Zealand, Nigeria, Norway, Poland, South Africa, Turkey, Algeria, 
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Bangladesh, Barbados, Burma, Cameroon, Colombia, Congo, Costa Rica, Cote D’Ivoire, Croatia, Czech 
Republic, Ecuador, Estonia, Ethiopia, France, Georgia, Ghana, Haiti, Iraq, Kenia, South Korea, Kuwait, 
Luxembourg, Macedonia, Malawi, Malaysia, Malta, Mauritius, Nepal, Pakistan, Peru, Philippines, 
Romania, Russia, Saudi Arabia, Serbia and Montenegro, Slovenia, Switzerland, Tanzania, Tunisia, 
Ukraine, United Arab Emirates, Vietnam, Zambia.     
b number of responses are over of number of participants due to multiple-choice selection 
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Table 2: Reported effects among patients with diabetes during COVID19 pandemic 
Characteristics (number of responses) Responses (%) 




















Method of diagnosis (78) 
RT-PCR SARS-CoV-2 
Serologic tests 













Exposed history (40) 
Any family member as a confirmed or probable case in the last 14 days 
Caregiver is a health care worker where a case had been diagnosed 
20 (50) 
5 (12.5) 
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Duration of disease (years) 
New onset 
Less than one  
1-5 
5-10 




































Shortness of breath 
 
Mean HbA1c, % (SD; range min-max) 
 
Therapies required 
Admission to hospital 
Admission to ICU 
Oxygen 
Bronchodilators and glucocorticoids 
Noninvasive ventilation 
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Boys 
Girls 
Duration of diabetes (years) 
Less than 3 
3-10 
















Mean HbA1c, % (SD; range min-max) 
 
Therapies required 
Admission to hospital 
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Oxygen 
Bronchodilators and glucocorticoids 
Noninvasive ventilation 







 DKA: Diabetic ketoacidosis: RT-PCR SARS-CoV-2: Reverse-Transcription-Polymerase Chain Reaction 
for detecting Severe acute respiratory syndrome coronavirus 2; SD: Standard deviation: ICU: 
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